Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma

Journal of Clinical Pathology

Volumn 60, Issue 6, 2007, Pages 664-669

  Chim, Chor Sang ^a,b   Liang, Raymond ^b   Fung, Tsz Kin ^b   Choi, Chi Lung ^b   Kwong, Yok Lam ^b  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; AZACITIDINE; CYCLOPHOSPHAMIDE; DEATH ASSOCIATED PROTEIN KINASE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISOLONE; PROTEIN MDM2; PROTEIN P14; PROTEIN P53; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; APOPTOSIS; ARTICLE; BONE MARROW; CANCER RADIOTHERAPY; CONTROLLED STUDY; EPIGENETICS; FEMALE; GENE SILENCING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METHYLATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS REGULATORY PROTEINS; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; AZACITIDINE; BASE SEQUENCE; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; DNA METHYLATION; DNA, NEOPLASM; EPIGENESIS, GENETIC; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MULTIPLE MYELOMA; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MDM2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34250827855     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2006.038331     Document Type: Article

References (31)

1. Kuehl WM, Bergsogel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002;2:175-87.
2. Hideshima T, Bergsagel PL, Kuehl WM, et al. Advances in biology of multiple myeloma: clinical applications. Blood 2004;104:607- 18.
3. Raveh T, Droguett G, Horwitz MS, et al. DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nat Cell Biol 2001;3:1-7.
4. Sherr CI. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001;2:731-7.
5. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004;432:307-15.
6. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770-6.
7. Peller S, Rotter V. TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Hum Mutat 2003;21:277-84.
8. Avet-Loiseau H, Li JY, Godon C, et al. P53 deletion is not a frequent event in multiple myeloma. Br J Haematol 1999;106:717- 19.
9. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
10. Chim CS, Liang R, Kwong YL. Gene promoter hypermethylation in hematologic malignancies. Hematol Oncol 2002;20:167-76.
11. Chim CS, Fung TK, Liang R. Disruption of INK4/CDK/Rb cell cycle pathway by gene hypermethylation in multiple myeloma and MGUS. Leukemia 2003;17:2533-5.
12. Chim CS, Kwong YL, Fung TK, et al. Methylation profiling in multiple myeloma. Leukemia Res 2004;28:379-85.
13. Chim CS, Fung TK, Cheung J, et al. SOCSI and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood 2004;103:4630-5.
14. Chim CS, Liang R, Fung TK, et al. Infrequent epigenetic dysregulation of CIP/KIP family of cyclin-dependent kinase inhibitors in multiple myeloma. Leukemia 2005;19:2352-5.
15. Salmon S, Cassady JR. Plasma cell neoplasms. In: DeVita VT, Hellman S, Rosenberg S, eds. Cancer, principles and practice of oncology. Philadelphia: JB Lippincott, 1997:2344.
16. Chim CS, Liang R, Tarn C, et al. P15 and P16 promoter mefhylation in acute promyelocytic leukemia. J Clin Oncol 2001;19:2033-40.
17. Chim CS, Tam C, Liang R, Kwong YL. P15 and P16 gene methylation in adult acute leukemia: lack of prognostic significance. Cancer 2001;91:2222-9.
18. Esteller M, Tortola S, Toyota M, et al. Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res 2000;60:129-33.
19. Chan EC, Lam SY, Tsang KW, et al. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary rumors and potential diagnostic application in bronchoalveolar lavage. Clin Cancer Res 2002;8:3741-6.
20. Inbal B, Cohen O, Polak-Charcon S, et al. DAP kinase links the control of apoptosis to metastasis. Nature 1997;390:180-4.
21. Esteller M, Com PG, Baylin SB, et al. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225- 9.
22. Katzenellenbogen RA, Baylin SB, Herman JG. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood 1999;93:4347-53.
23. Ng MH, To KW, Lo KW, et al. Frequent death-associated protein kinase promoter hypermethylation in multiple myeloma. Clin Cancer Res 2001;7:1724-9.
24. Chim CS, Liang R, Leung MH, et al. Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma. J Clin Pathol 2007;60:104-6.
25. Nagy E, Beck Z, Kiss A, et al. Frequent methylation of p16INK4A and p14ARF genes implicated in the evolution of chronic myeloid leukaemia from its chronic to accelerated phase. Eur J Cancer 2003;39:2298-305.
26. Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, et al. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood 2004;104:2492-8.
27. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2003;17:1813-19.
28. Seidl S, Ackermann J, Kaufmann H, et al. DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies. Cancer 2004;100:2598-606.
29. Taniguchi T, Chikatsu N, Takahashi S, et al. Expression of p16INK4A and p14ARF in hematological malignancies. Leukemia 1999;13:1760-9.
30. Drexler HG. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 1998;12:845-59.
31. Soengas MS, Capodieci P, Polsky D, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001;409:207-11.